Literature DB >> 6993183

Danazole in the treatment of hereditary angioedema.

S W Hosea, M M Frank.   

Abstract

Danazol is an effective agent for the prophylaxis of the recurrent attacks of mucocutaneous and visceral swelling which occur in patients with hereditary angioedema (HAE). Danazol apparently increases the synthesis of the inhibitor of the first component of complement which is partially deficient in these heterozygous individuals. The efficacy of danazol in this condition appears to be limited only by the occurrence of adverse effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993183     DOI: 10.2165/00003495-198019050-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  4 in total

1.  Hereditary angioedema: the clinical syndrome and its management.

Authors:  M M Frank; J A Gelfand; J P Atkinson
Journal:  Ann Intern Med       Date:  1976-05       Impact factor: 25.391

2.  Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery.

Authors:  C J Jaffe; J P Atkinson; J A Gelfand; M M Frank
Journal:  J Allergy Clin Immunol       Date:  1975-06       Impact factor: 10.793

3.  Long-term therapy of hereditary angioedema with danazol.

Authors:  S W Hosea; M L Santaella; E J Brown; M Berger; K Katusha; M M Frank
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

4.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.

Authors:  J A Gelfand; R J Sherins; D W Alling; M M Frank
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

  4 in total
  2 in total

Review 1.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

2.  Anti-cholesterol antibody levels in hereditary angioedema.

Authors:  Lilian Varga; Adrienn Bíró; Gábor Széplaki; Luca Tóth; Anna Horváth; George Füst; Henriette Farkas
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.